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In silico screening for human 
norovirus antivirals reveals a novel 
non-nucleoside inhibitor of the viral 
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Human norovirus causes approximately 219,000 deaths annually, yet there are currently no antivirals 
available. A virtual screening of commercially available drug-like compounds (~300,000) was performed 
on the suramin and PPNDS binding-sites of the norovirus RNA-dependent RNA polymerase (RdRp). 
Selected compounds (n = 62) were examined for inhibition of norovirus RdRp activity using an in vitro 
transcription assay. Eight candidates demonstrated RdRp inhibition (>25% inhibition at 10 µM), which 
was confirmed using a gel-shift RdRp assay for two of them. The two molecules were identified as initial 
hits and selected for structure-activity relationship studies, which resulted in the synthesis of novel 
compounds that were examined for inhibitory activity. Five compounds inhibited human norovirus 
RdRp activity (>50% at 10 µM), with the best candidate, 54, demonstrating an IC50 of 5.6 µM against the 
RdRp and a CC50 of 62.8 µM. Combinational treatment of 54 and the known RdRp site-B inhibitor PPNDS 
revealed antagonism, indicating that 54 binds in the same binding pocket. Two RdRps with mutations 
(Q414A and R419A) previously shown to be critical for the binding of site-B compounds had no effect on 
inhibition, suggesting 54 interacts with distinct site-B residues. This study revealed the novel scaffold 54 
for further development as a norovirus antiviral.
Human norovirus is responsible for over 200,000 global deaths, USD $60 billion in societal costs, and USD $4.2 
billion in health expenditure each year1. While norovirus-induced illness is usually self-limiting in healthy indi-
viduals, the disease can be severe or life threatening in immunocompromised and immunosuppressed patients2,3, 
neonates4, young children5,6 and elderly populations7,8. As such, a significant research effort has been invested 
to identify antiviral candidates for the treatment of norovirus infections and for prophylactic use in outbreak 
settings.
Several factors have hampered norovirus antiviral research, including the inability to successfully propagate 
human norovirus in cell culture until recently9,10. However, the recently developed human norovirus culture 
systems are not readily amenable to antiviral screening due to low replication levels, with only 100- to 1000-fold 
increases in viral titres9,10, and the systems’ complexities and costs. Most norovirus antiviral research currently 
relies on the closely related murine norovirus (MNV), for screening potential human antivirals due to its robust 
and reliable culture, and available mouse models11.
The only norovirus antiviral in clinical trials to-date is the broad-spectrum antimicrobial compound nitazoxa-
nide12 (Fig. 1). This compound has successfully treated one immunosuppressed patient13, and reportedly reduced 
the duration of symptoms in both norovirus and rotavirus infected patients12. However, the exact mode of action 
of nitazoxanide against norovirus is still unknown, and more research is required to establish its antiviral target.
There are a small number of human norovirus antiviral candidates in preclinical development. The major-
ity of these therapeutic candidates target the viral RNA-dependent RNA polymerase (RdRp)14–17, or the viral 
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protease18–20, due to their critical role in viral replication, and their lack of cellular homologues21,22. RdRp-targeted 
antivirals fall into two classes; nucleoside analogues (NAs) and non-nucleoside inhibitors (NNIs)23. NA prodrugs 
can be phosphorylated after cellular uptake, then incorporated into the growing viral nucleic acid chain by the 
RdRp24. These antivirals work by competing with incoming nucleoside triphosphates (NTPs) to cause either 
chain termination25, or lethal mutagenesis of the progeny virus26. NAs have proven successful in the treatment 
of several viral infections including hepatitis B virus27, hepatitis C virus (HCV)28, herpesviruses29 and human 
immunodeficiency virus (HIV)30. However, due to their mode of action, they frequently result in off-target side 
effects31,32, and no NAs have yet reached clinical trials for norovirus treatment. One NA, 2′-C-methylcytidine 
(2CMC) (Fig. 1), inhibited the human norovirus RdRp, with a reported half maximal inhibitory concentration 
(IC50) of 2.5 µM15, and a half maximal effective concentration (EC50) of 8.2 µM in cell culture against the human 
norovirus replicon15. More recently, 2CMC was also found to be effective against human norovirus cultured in 
the B-cell culture system, with a reported EC50 of 0.3 µM33. However, despite these promising preclinical results, 
development of the oral 2CMC prodrug (valopicitabine) (Fig. 1) for the treatment of HCV patients was termi-
nated after gastrointestinal effects were reported, and further development against other viruses including human 
norovirus is now unlikely.
Unlike NAs, NNIs generally bind to allosteric pockets on the viral polymerase to prevent conformational 
changes necessary for transcription34. NNIs have been clinically approved for treating HIV35 and HCV36 infec-
tions, however, while several potential norovirus NNIs have been identified in pre-clinical studies14,16,17,37–39, 
none are in clinical trials for the treatment of human norovirus infections. Amongst these pre-clinical candi-
dates is the anthelmintic drug suramin (Fig. 1), which demonstrated potent in vitro inhibitory activity against 
the human norovirus RdRp in enzymatic assays with an IC50 of 27.0 nM37. Similarly, the suramin derivative, 
pyridoxal-5′-phosphate-6-(2′-naphthylazo-6′-nitro-4′,8′-disulfonate) tetrasodium salt (PPNDS) (Fig. 1), has also 
been shown to inhibit human norovirus RdRp activity in vitro, with an IC50 of 0.45 µM17. Recently, PPNDS was 
reported to exhibit broad-spectrum antiviral activity against other calicivirus RdRps16. However, neither of these 
compounds are likely to be suitable for the treatment of human norovirus infections, as both suramin and PPNDS 
display poor cell membrane permeability17,40, suramin induces severe side-effects41,42, and PPNDS is known to 
have non-specific, off-target activity43.
The human norovirus polymerase forms the canonical ‘right-hand’ RdRp structure, with fingers, palm and 
thumb domains44. To-date, three NNI binding sites have been identified on the norovirus RdRp, including the 
NTP pathway, site-A in the fingers domain and site-B in the thumb domain17,37. Co-crystallisation studies of 
the norovirus RdRp and suramin identified its binding pocket in the NTP access pathway, between the fingers 
and thumb domains37. Site-A lies within a positively charged cleft for NTP traversal, but due to highly flexi-
ble amino acid side-chains it is less suitable as an NNI target, due to challenges for structure-based antiviral 
design17. However, site-B is a highly conserved binding site within the thumb region and can be exploited for both 
structure-activity and targeted de-novo antiviral design of novel compounds against human norovirus16.
Figure 1. Norovirus inhibitors in pre-clinical studies. Nitazoxanide (1), 2′-C-methylcytidine (2), valopicitabine 
(3), PPNDS (4), suramin (5).
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This study aimed to identify promising chemical scaffolds for antiviral development targeting the human 
norovirus RdRp. To achieve this aim, a series of structure-based and ligand-based virtual screenings were carried 
out on approximately 300,000 commercially available compounds with favourable drug-like properties, to iden-
tify binding capabilities focused primarily on the suramin and PPNDS binding-sites of the norovirus RdRp. This 
in silico screening identified 62 compounds that were examined for inhibition of norovirus RdRp activity using 
polymerase assays. Two molecules were found to have an interesting RdRp inhibitory activity and were selected 
for a structure-activity relationship study synthesising new chemical derivatives. Among the newly prepared 
compounds, we identified a lead candidate site-B binder, which inhibited the human norovirus RdRp at a low 
micromolar concentration. This study revealed a novel NNI that presents a promising scaffold for further chemi-
cal enhancement, to improve potency and specificity, in the pursuit of effective norovirus antivirals.
Results and Discussion
Molecular Modelling: hit identification. Two different virtual screening approaches have been used for 
the initial selection of potential hit compounds: a structure-based virtual screening and a ligand-based virtual 
screening. While the first approach takes into consideration the protein structure and the ligand spatial disposi-
tion in relation to the active site (pharmacophore features), the ligand-based methodology compares the shapes 
of known ligands with unknown ones, evaluating two-dimensional similarities (i.e. same functional groups) 
or three-dimensional similarities (molecule occupational volume) without considering the protein structure45. 
The molecules selected with the two methods were then subjected to different molecular docking evaluations 
described below.
Structure-based virtual screening. The norovirus RdRp was used to perform a structure-based virtual 
screening of the SPECS library, a database of ~300,000 commercially available compounds46. In particular, two 
screens were conducted using two different RdRp crystal structures: the MNV RdRp co-crystallised with suramin 
(PDB ID: 3UR0, 62% identity with the human norovirus RdRp)37 and the human RdRp co-crystallised with 
PPNDS (PDB ID: 4LQ3)17. Suramin inhibits human norovirus and MNV RdRp activity through a mixed inhi-
bition mode (nucleic acid and GTP) and occupies site-A. Site-A encompasses the access route for the incoming 
NTP that is linked to the nascent RNA chain. PPNDS inhibits human norovirus RdRp activity by blocking the 
access of both the ssRNA template and the NTPs, and occupies the inner pocket of site-B, which is located in the 
RdRp thumb domain17. The two binding sites are very close to each other and overlap in the central part of the 
protein structure.
The SPECS database of compounds was pre-filtered using a pharmacophore model based on the suramin 
binding site in one case and on the PPNDS binding site in the second case (Fig. 2A,B). The required structural 
features of the suramin pharmacophore were identified in 4838 structures, whereas 5206 matched the PPNDS 
model. These two sub-libraries were then docked using PLANTS software47 on the suramin and on the PPNDS 
binding sites, respectively. The docking results (docking poses) obtained for each binding site were subsequently 
re-scored using other two different docking programs: LeadIT-FlexX and Glide XP48,49. Applying an internal 
consensus score procedure, a methodology validated by our research group in the past50, the values of the three 
different scoring functions for each docking pose were analysed together. Only the docking poses falling in the 
top 25% of the score value range in all the three scoring functions were considered as hits. 799 compounds were 
selected for the suramin pocket, 755 for the PPNDS. A final selection was made by visually inspecting the dock-
ing poses of the different molecules and their potential binding to the target sites (see experimental section). 19 
derivatives were selected for the suramin binding site and 20 for the PPNDS site. The molecules were purchased 
and screened for inhibition of norovirus RdRp activity using a transcription enzyme assay.
Ligand-based virtual screening. A shape-based screening of the SPECS library, previously prepared with 
the Omega conformations generator program, was performed using ROCS 3D51. Two different queries were gen-
erated: one based on the partial structure of suramin, and a second prepared on the PPNDS structure (Fig. 3A,B). 
In both cases, the occupational volume of the two molecules was generated and the relevant chemical properties 
of each ligand were included as pharmacophore features. The two queries were used to pre-filter the SPECS data-
base; 6563 molecules matched the shape and electrostatic features (Tanimoto combo score) of suramin, whereas 
6571 resulted from the PPNDS query. Also in this screen, the two new sub-libraries were then docked using 
PLANTS software on the suramin and on the PPNDS binding sites respectively. After the consensus score proce-
dure and a final visual inspection (see experimental section), three compounds were selected for suramin and 20 
for PPNDS. The new derivatives were purchased and biologically evaluated.
Biological Evaluation
Two candidates inhibit norovirus RdRp activity. The 62 compounds identified in silico were screened 
for inhibition of norovirus RdRp activity using an in vitro fluorescent, de novo RdRp assay52. Compounds were 
tested at fixed concentrations of 10 µM and 100 µM, and compared to mock treated samples containing the vehi-
cle only (0.5% DMSO [vol/vol]) (Fig. 4A,B). Of the 62 compounds examined, five (Fig. 4C) exhibited more than 
25% inhibition of human norovirus RdRp activity at 10 µM (Fig. 4A) and more than 50% at 100 µM (Fig. 4B). For 
certain compounds, significant insolubility was observed, coupled with either inherent fluorescence quenching 
(positive y-axis values on Fig. 4A,B) or enhancement of the fluorescence signal (negative y-axis values). Therefore, 
a secondary assay that does not rely on relative fluorescence was employed as an effective counter-screen to 
exclude false positives and compounds that showed enhanced fluorescence.
In addition, some compounds (i.e. AJ-077/33270018 and AP-970/12851847) exhibited insolubility, innate 
fluorescence and even apparent RdRp enhancement at 100 µM (negative y-axis values Fig. 4B). Therefore, they 
were counter-screened at 100 µM in a secondary gel-based assay (Supplementary Fig. S1). The putative RdRp 
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activity enhancement observed in the primary fluorescent assay was not seen in the gel-based assay, confirming 
compound insolubility and innate fluorescence that was likely affecting assay results.
To confirm RdRp inhibition and to exclude any potential false positives from the first fluorescence RdRp 
assay, the eight selected compounds (Fig. 4C) were then assessed using a gel-shift enzyme activity assay. These 
eight compounds included five that demonstrated dose-dependent inhibition (red bars, compounds 6, 7, 9, 11 
and 13) reaching over 25% inhibition at 10 µM and more than 50% inhibition at 100 µM. Three additional com-
pounds (compounds 8, 10 and 12) that reached more than 25% inhibition at both 10 and 100 µM were selected 
Figure 2. Pharmacophore models used for the structure-based virtual screening. (A) Model based on suramin 
binding to the MNV RdRp 3UR0 crystal structure. The model consists of three aromatic features (purple, 
green and turquoise), one hydrogen bond acceptor (pink) and two hydrogen bond acceptors or anionic groups 
(orange and yellow). Only the interacting portion of suramin has been considered for the pharmacophore 
creation. (B) Model based on PPNDS binding to the human norovirus RdRp 4LQ3 crystal structure. The model 
consists of two aromatic features (purple and green), three hydrogen bond acceptors and anionic groups (pink, 
turquoise and yellow) and one hydrogen bond donor and acceptor. Exclusion volumes are hidden for clarity. 
The two binding site areas are represented as molecular surface. The MNV RdRp structure is shown as dark 
green ribbon, while the human norovirus RdRp is represented as salmon ribbon.
Figure 3. Queries generated using vROCS. (A) Query generated using the partial structure of suramin. 
(B) Query generated using the structure of PPNDS. The overall molecular shape of both the inhibitors is 
represented as a grey surface, while the chemical features considered are an H-bond acceptor (red sphere) and 
hydrophobic/aromatic centres (green spheres).
www.nature.com/scientificreports/
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Figure 4. Initial screen for inhibition of human norovirus Sydney 2012 RdRp activity. The effects of 62 
compounds were examined against norovirus RdRp activity using a fluorescent activity assay at 10 µM (A) and 
100 µM (B). Five compounds that exhibited more than 25% inhibition at 10 µM and 50% inhibition at 100 µM 
(red bars) and three soluble compounds that exhibited more than 25% inhibition at both concentrations (green 
bars) were chosen for further assessment with a counter-screen gel-shift RdRp assay. The positive control (blue 
bars) is a previously reported norovirus NNI RdRp inhibitor NIC02 (10 µM in (A) and 100 µM in (B)14. The 
mean values of triplicate datasets with standard deviation are shown. (C) Structure of the eight most potent 
compounds with 11 and 13 highlighted. (D) A counter-screen gel-shift assay was used to confirm norovirus 
RdRp inhibitory activity of hit compounds. The eight compounds were examined for inhibition of primed 
elongation activity. PE44-NoV RNA templates (32 nucleotides) were extended (44 nucleotides) by the RdRp in 
the absence of any test compounds (0.5% DMSO [vol/vol] negative control) or with test compounds at a fixed 
concentration of 100 µM. The nucleoside analogue 3′-deoxyguanosine-5′-triphosphate is used as a positive 
control (10 µM) to demonstrate complete inhibition, and no RdRp was used as a negative control. Full-length 
gels are presented in Supplementary Fig. S2.
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for counter-screening. The three compounds (green bars) were examined using the gel-based assay due to the 
unusual behaviour of demonstrating higher inhibition at 10 µM compared to 100 µM, potentially due to solubility 
issues. Two additional compounds (AE-562/12222591 and AK-968/41925073) demonstrated more than 25% 
inhibition at 10 and 100 µM but were not pursued further as they both precipitated heavily in 100% DMSO and 
therefore lacked the desirable drug-like property of solubility.
In this assay, a 32 nucleotide RNA template (PE44-NoV) is extended to 44 nucleotides in the presence of an 
active RdRp16. The NA 3′-deoxyguanosine-5′-triphosphate (3′dGTP) was used as a positive control and exhibited 
complete inhibition of transcription at 10 µM. Inhibition of primed elongation of the PE44-NoV template was 
examined at a fixed concentration of 100 µM (Fig. 4D). In the absence of inhibition (0.5% DMSO vehicle only) the 
RNA template was extended to 44 nucleotides (Fig. 4D), evidenced by an upward gel shift and the appearance of 
the second, higher band. Only two of the eight compounds, 11 and 13, exhibited complete inhibition of norovirus 
RdRp activity at 100 µM (Fig. 4D), while the remaining six compounds (6–10 and 12) only demonstrated partial 
inhibition of primed elongation activity, and were excluded from further development. Based on these results, we 
decided to focus our attention on these two molecules.
Chemistry
Due to their confirmed inhibitory activity against the RdRp polymerases, the structures of 11 and 13 were chosen 
as starting point for the preparation of a series of analogues, with which to explore the structure-activity relation-
ships associated with the two scaffolds.
Hit 13 modified analogues. 13 is characterized by a methylbenzoic acid portion and a morpholine ring 
part linked by a central furan-2-yl-methylene-thiazolidine-2,4-dione core. We focused our initial synthetic efforts 
on the two lateral portions of the molecule, without modifying the central core, in order to investigate the role of 
these two parts in the RdRp inhibitory activity.
The synthetic pathway reported in Fig. 5 was obtained after several optimizations of reaction methods and 
routes. The differently substituted phenylfuran-2-carbaldehydes 16a–d were prepared by reacting the corre-
sponding phenylboronic acids (14a–d) with 5-bromofuran-2-carbaldehyde (15) in a mix of tetrahydrofuran/
water, through a Suzuki coupling reaction using sodium carbonate (Na2CO3) as base and tetrakis (Pd[Ph]3]4) 
as catalyst modifying a reported procedure53. The desired products were obtained in a very good yield range 
(62–98%) after flash column chromatography purification. A Knoevenagel condensation was exploited for the 
preparation of derivatives 18a–d by reacting compounds 16a–d with thiazolidine-2,4-dione (17), using β-alanine 
as catalyst and acetic acid as solvent53. In the final step, compounds 18a–d were converted into the corresponding 
final products 23a–c, 24a–d, 25a–d by reacting them with 20–22 in dimethylformamide (DMF) at 60 °C for 72 h 
using potassium carbonate (K2CO3) as base54. The final compounds were obtained in a good yield range (42–76%) 
after either re-crystallization or flash column chromatography purification. Compounds 20–22 were previously 
prepared by reacting 2-bromoacetyl chloride (19) with different secondary amines in dichloromethane (DCM) 
and N,N-diisopropylethylamine (DIPEA) as base55. Synthetic efforts were made to achieve good yields for this 
step by monitoring the reaction temperature and evaluating different bases. Following this synthetic route, 11 
derivatives of 13 were prepared.
As reported above, 13 presents a free acid group, therefore a basic hydrolysis of 23b with LiOH in water and 
methanol at room temperature was attempted. Unfortunately, NMR analysis revealed complete degradation of 
the starting material with the opening of the thiazolidinedione ring, revealing instability for these compounds 
in basic environments. A second attempt was made by performing an acid hydrolysis in HCl 6 M increasing the 
Figure 5. General synthetic procedure followed for the preparation of 23a-c, 24a-d, 25a-d. (i) Na2CO3, 
Pd(PPh3)2, THF/H2O, r.t. 8 h, 60 °C 12 h; (ii) β-alanine, AcOH, 100 °C 1 h; (iii) K2CO3, DMF, r.t. o.n., 60 °C 72 h; 
(iv) secondary amine, DIPEA, DCM, 0 °C to r.t. 20 min.
www.nature.com/scientificreports/
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reaction temperature to 100 °C over 3 days. In this case, the desired hydrolysis did not take place and the starting 
ester was recovered.
In the attempt to find a strategy to prepare the free acid derivatives, the previously used synthetic pathway 
was slightly modified, as reported in Fig. 6, by performing the ester hydrolysis of 16b as second step after the 
Suzuki coupling, obtaining 26. Hydrolysed 26 was then condensed with 17 to give 27. In the last step, the reaction 
between 27 and 20 did not yield the desired product 28, the unreacted staring materials were recovered, along 
with small amounts of a minor by-product, 29, in which the substitution of the bromide compound occurred on 
the carboxylic acid portion of the molecule instead of the thiazolidinedione ring, as also reported by Zhang et al.56. 
The free acid seems to interfere with the SN2 reaction and a different approach was therefore investigated.
Figure 7 shows the planned modifications to the original synthetic pathway to prepare 28. In this case, the 
Knoevenagel condensation was performed as a first step giving 30. Nucleophilic substitution with 20 gave the 
central furan-2-yl-methylene-thiazolidine-2,4-dione core with the attached morpholine ring portion (31). For 
the last step, the Suzuki coupling between the 4-boronobenzoic acid 32, previously prepared starting from its 
ester derivative (14b), and 31 was attempted, but no desired product was obtained, recovering the unreacted 
boronic acid and observing degradation of the thiazolidinedione ring.
A final and alternative method for the preparation of the desired free acid 28 was developed, considering the 
target molecule as an assembly of two portions: the 4-(5-formylfuran-2-yl)benzoic acid (26), prepared by Suzuki 
coupling (Fig. 6), and the 3-(2-morpholino-2-oxoethyl)thiazolidine-2,4-dione (33), obtained by the SN2 reaction 
between 17 and 20. The two portions were then linked together in the last step through a Knoevenagel condensa-
tion affording the desired product 28 with the free acid (Fig. 8). This new approach was used for the preparation 
of other seven final compounds, including the original hit 13, that could be used as reference for the new biologi-
cal evaluation (Fig. 9). Also for this synthetic pathway, the different steps were optimised to afford a high yield. In 
particular, for the preparation of the thiazolidine-2,4-dione derivatives (35–38), the reaction conditions needed 
to be changed according to the substituted amine present. In the case of piperidine and dimethylamine derivatives 
(36, 37), the use of sodium hydride (NaH) as base and THF as solvent gave a less impure reaction and a higher 
yield if compared to the method used for the other derivatives.
Hit 11 modified analogues. 11 has a central furan-2-ylmethylene-pyrazolidine-3,5-dione core substi-
tuted at position 1 of the pyrazolidine with a methyl benzene and at position 5 of the furane ring with a thiazol
-2-yl-benzenesulfonamide. A five-step synthetic pathway was developed and optimised and a small family of two 
new derivatives was prepared in order to initially understand the role of the methyl group and the thiazole ring.
Figure 6. Alternative method for the preparation of the free acid derivative. (i) β-alanine, AcOH, 100 °C 1 h; (ii) 
K2CO3, DMF, r.t. o.n., 60 °C 72 h.
Figure 7. Alternative method for the preparation of the free acid derivatives (i) β-alanine, AcOH, 100 °C 1 h; 
(ii) K2CO3, DMF, r.t. o.n., 60 °C 72 h; (iii) Na2CO3, Pd(PPh3)2, THF/H2O, r.t. 8 h, 60 °C 12 h.
Figure 8. Preparation of the free acid derivative 28 (i) K2CO3, DMF, r.t. o.n., 60 °C 72 h; (ii) β-alanine, AcOH, 
100 °C 1 h.
www.nature.com/scientificreports/
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Hydrazides 46–47 were prepared by reacting the corresponding phenylhydrazines (43–44) with ethyl-
3-chloro-3-oxopropanoate (45) in THF and triethylamine (Et3N), following a reported methodology57. 46–47 
were then converted into the corresponding 1-phenylpyrazolidine-3,5-dione 48–49 through an ester displace-
ment reaction in the presence of sodium hydroxide (NaOH) and ethanol (EtOH)57. 4-Bromobenzene-1-sulfonyl 
chloride (50) and aniline 51 in pyridine gave sulfonamide 52, which was then converted in 53 by a Suzuki cou-
pling. In particular, synthetic efforts were made to find the best conditions for this coupling, since the procedure 
previously described did not work and only the starting materials were recovered after each attempt, potentially 
due to an interference of the sulfonamide bond with the catalyst used. After changing solvent systems, reaction 
temperature, base and phosphine ligands, the best reaction conditions were found using potassium phosphate 
(K3PO4) as base, Pd(dppf) as catalyst, water/DMF as solvent and heating in a microwave reactor at 130 °C, which 
gave the desired product in a good yield (61%).
In the last step (Fig. 10), the two portions were linked together by reacting 48–49 and 53 according to a 
Knoevenagel condensation, giving the desired products 54 and 55.
Biological Evaluation
Three newly prepared compounds inhibit human norovirus RdRp activity. The newly synthesised 
compounds, including the re-prepared hit 13 and some synthesis intermediates (Table 1), were initially evaluated 
on norovirus Sydney 2012 RdRp activity in vitro using a quantitative fluorescent assay. Compounds were tested at 
a fixed concentration of 10 μM and compared to the relative activity of mock treated samples.
Results of the assay are reported in Fig. 11A. The re-prepared 13 demonstrated a similar level of inhibi-
tion compared to the initial screening data (25% inhibition at 10 µM, cf. 37% inhibition at 10 µM for the com-
mercial variant), further supporting the reproducibility of the assay and more importantly confirming the 
RdRp inhibitory activity associated with this particular molecule. The shorter phenylfuran-2-yl-(methylene)
thiazolidine-2,4-dione derivatives (18a, 18c, 27), regardless of the substituent on the aromatic ring, and the 
furan-2-yl(methylene)-3-(morpholine-4-carbonyl)thiazolidine-2,4-dione (31) lacked RdRp inhibitory activity, 
indicating that RdRp inhibition was associated with the whole scaffold of 13 and not only with the methylben-
zoic acid portion or the morpholine ring part. These derivatives are likely too small to entirely occupy the RdRp 
binding site area to block polymerase activity. The overall RdRp inhibitory activity of the derivatives of 13 seems 
to be the result of the combination of the two portions forming the molecule. In the morpholine derivatives, 
the most important influence for the activity was given by the free acid in position para of the aromatic ring. 
In fact, its removal (23a, 23c) or its conversion to a methyl ester (23b, 39d) lead to a complete loss of activity, 
Figure 9. General synthetic procedure followed for the preparation of 13, 39d, 40e, 41e, 42a-c. (i) Na2CO3, 
Pd(PPh3)2, THF/H2O, r.t. 8 h, 60 °C 12 h; (ii) secondary amine, DIPEA, DCM, 0 °C to r.t. 20 min; (iii) K2CO3, 
DMF, r.t. o.n., 60 °C 72 h or NaH, THF, 60 °C, 24 h; (iv) β-alanine, AcOH, 100 °C 1 h.
Figure 10. General synthetic procedure followed for the preparation of 54, 55. (i) NEt3, THF, r.t. 3 h; (ii) NaOH, 
EtOH, r.t. 30 min; (iii) pyridine, r.t. o.n.; (iv) K3PO4, Pd(dppf), H2O/DMF, 130 °C 75 min (microwave); (v) 
AcOH, 120 °C 3 h.
www.nature.com/scientificreports/
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whereas the derivative bearing only the free acid (28) showed improved activity when compared with the initial 
hit, inhibiting the RdRp activity by almost 50%. The methyl group at position ortho seems irrelevant for inhib-
itory activity, as demonstrated by the lack of activity of 23c, and its removal, together with the presence of the 
free acid, lead to a significant increment of inhibitory activity. In the piperidine compounds, an unsubstituted 
aromatic ring (24a) and an ortho methyl substituent (24c) are related with the loss of inhibitory activity, giving 
the same result obtained for the morpholine series. Replacement of the morpholine ring with piperidine (40e) 
in the original structure of 13 abolished the activity, whereas esterification of the same derivative (24d) resulted 
in 25% inhibition, similar to the initial hit. Removal of the ortho methyl group of 24d (24b) increased the degree 
Compound R1 X Compound R1 X
13 2-Me, 4-COOH 25c 2-Me
23a H 25d 2-Me, 4-COOMe
23b 4-COOMe 41e 2-Me, 4-COOH
23c 2-Me 42a H
28 4-COOH 42b 4-COOMe
39d 2-Me, 4-COOMe 42c 2-Me
24a H 18a S.I.
24b 4-COOMe 18c S.I.
24c 2-Me 27 S.I.
24d 2-Me, 4-COOMe 31 S.I.
40e 2-Me, 4-COOH 29 S.P.
25a H 54
25b 4-COOMe 55
Table 1. Newly prepared compounds evaluated on recombinant norovirus Sydney 2012 RdRp activity in vitro 
assay. S.I. = synthesis intermediate; S.P. = side product.
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of RdRp inhibitory activity up to 60%, compared with 13, confirming the detrimental effect of the ortho methyl 
group. Replacing the morpholine ring with a non-cyclic secondary amine, such as the dimethyl amine, slightly 
improved the activity compared to the initial hit, but a maximum of 45% inhibition at 10 µM was reached. Also 
in this case, the presence of the acid or the ester seems fundamental for activity retention (25a, 25c). Insertion of 
an aniline moiety, in replacement of the morpholine, had a positive impact on inhibitory activity, with derivative 
42a, characterised by the unsubstituted aromatic ring on one side and the aniline on the other side, reaching 75% 
RdRp inhibition at 10 µM.
Hit 11 derivatives, in which the original thiazole ring has been replaced by an unsubstituted phenyl ring, 
showed 75% RdRp inhibition, with no substantial differences between the methyl benzene and the unsubstituted 
phenyl derivative (55 vs. 54), and an activity comparable with the inhibition found in the initial screening for 11.
Among the tested compounds, five (24b, 42a, 42b, 54, 55) demonstrated more than 50% inhibition of the 
human norovirus Sydney 2012 RdRp at 10 µM (Fig. 11A). To confirm RdRp inhibition, a gel-shift activity assay 
was again used to examine the five selected compounds at a fixed concentration of 100 µM (Fig. 11B) and three 
of the five compounds exhibited near complete abolishment of norovirus RdRp activity (42a, 42b, 54), whilst 55 
only displayed minimal inhibition and 24b had no appreciable effect.
Four compounds have low micromolar IC50 values against human norovirus RdRp. The 
two initial hits identified from the virtual screening (11 and 13), and the three newly synthesised derivatives, 
which exhibited near complete abolishment of norovirus RdRp activity in the gel-based assay (42a, 42b, 54), 
were further assessed using a fluorescent RdRp assay to ascertain IC50 values (concentration range examined: 
0.1–100 µM). Dose-dependent inhibitory response curves were used to establish IC50 values for the five test 
compounds (Table 2). While IC50 values could be attained for four of the five compounds tested, 42b displayed 
significant solubility issues, even in the 100% DMSO solvent. Therefore, 42b was too insoluble to attain a reliable 
confidence interval in the dose-response experiments and was not examined further. However, from the other 
four compounds, hit 11 and its phenyl derivative 54 gave the lowest IC50 values, 3–5 fold improved compared with 
13 and its derivative 42a, confirming increased RdRp inhibitory activity associated with this scaffold.
Figure 11. Secondary screen for inhibition of human norovirus Sydney 2012 RdRp activity. (A) The inhibitory 
effects of 26 compounds were examined against norovirus RdRp activity using a fluorescent activity assay at 
10 µM. Five compounds that exhibited more than 50% inhibition (red bars) were chosen for further assessment 
with a counter-screen gel-shift RdRp assay. The positive control (blue bar) is the norovirus NNI RdRp inhibitor 
NIC0214. The mean values of triplicate datasets with standard deviations are shown. (B) A counter-screen-gel-
shift assay was used to confirm norovirus RdRp inhibitory activity of the five compounds identified in panel 
(A). PE44-NoV RNA templates (32 nucleotides) were extended (44 nucleotides) by the RdRp in the absence of 
any test compounds (0.5% DMSO [vol/vol] negative control) or with test compounds at a fixed concentration of 
100 µM. The nucleoside analogue 3′-deoxyguanosine-5′-triphosphate (3′dGTP) was used as a positive control 
(10 µM) to demonstrate complete inhibition, and no RdRp was used as a negative control. Full-length gels are 
presented in Supplementary Fig. S3.
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Broad-spectrum calicivirus RdRp inhibitory activity. The antiviral activity of the four compounds (11, 
13, 42a and 54) were examined for inhibition of RNA polymerases from other viruses spanning three genera of 
the Caliciviridae family, including Norovirus (human norovirus and MNV), Lagovirus (rabbit haemorrhagic dis-
ease virus [RHDV]) and Sapovirus (human sapovirus). All four compounds examined exhibited broad-spectrum 
inhibitory activity of the calicivirus RdRps at a fixed concentration of 100 µM, ranging between 44.4% inhi-
bition (42a with MNV RdRp) through to 99.0% inhibition; (54 with RHDV RdRp) (Fig. 12A). The protein 
sequence of the examined calicivirus polymerases has an identity range between 30.2–61.4%, and therefore the 
broad-spectrum activity of these compounds could be attributed to a common, highly-conserved binding pocket 
across the RdRps, as has been previously reported with broad-spectrum activity of other site-B binding NNIs16. 
Moreover, the ability of each compound to inhibit the different RdRps in a similar range could be further confir-
mation of targeting a well-conserved binding site of the Caliciviridae family.
To ensure the four hit compounds selectively inhibited calicivirus polymerase activity, they were further coun-
ter screened against a viral-like RdRp (bacteriophage Φ6) and an RNA-dependent DNA polymerase Moloney 
murine leukaemia virus reverse transcriptase (MMLV RT). None of the lead compounds reached 50% inhibition 
of the Φ6 and MMLV polymerases examined up to 100 μM (Supplementary Fig. S4). Overall, this demonstrated 
specificity for the calicivirus RdRps, in particular for the human Sydney 2012 RdRp (Fig. 12A and Supplementary 
Fig. S4).
MNV RdRp activity and cell culture evaluation on 54. As mentioned above, the only robust cellular 
assay available for the evaluation of potential norovirus inhibitors is the closely related MNV assay. Out of the 
novel compounds examined (54 and 42a; Fig. 12A), 42a demonstrated weak inhibition of MNV RdRp activity 
(<50% at 100 µM in Fig. 12A), which did not warrant further testing in cell culture. Evaluation of compounds 
11 and 13 against MNV plaque formation in cell culture58 at two fixed concentrations of 10 and 100 µM did 
not give promising results. Compound 11 demonstrated 37.1% ± 2.7% inhibition of MNV plaque formation at 
10 µM, but was cytotoxic at 100 µM, while compound 13 only reached 21.0% ± 1.2% inhibition of MNV plaque 
formation at 100 µM with no substantial differences between 10 and 100 µM (Supplementary Fig. S5). Compound 
54, a novel chemical entity, demonstrated the broadest spectra of antiviral activity across the four RdRps, and 
the highest level of inhibition of the MNV RdRp (Fig. 12A). Consequently, 54 was further assessed to determine 
the IC50 value against MNV RdRp activity using an in vitro fluorescent assay. 54 (0.1–100 µM) displayed an IC50 
of 12.1 µM against MNV RdRp (Fig. 12B). 54 was then assessed for cytotoxicity against RAW264.7 mouse mac-
rophage cells using a cell viability assay. 54 (0.5–100 µM) exhibited a mean half maximal cytotoxic concentration 
(CC50) of 62.8 µM (Fig. 12C). Using the plaque reduction assay, the inhibitory effects of 54 (0.5–50 µM) were 
examined against MNV plaque formation in cell culture. There was no appreciable effect on plaque numbers 
up to 25 µM, with RAW264.7 cells thinning at 50 µM, due to cytotoxicity (Fig. 12D). While 54 demonstrated an 
IC50 of 12.1 µM against the MNV RdRp in vitro, it had little effect against MNV in cell culture (EC50 > 50 µM). 
This could be due to poor cell membrane permeability of 54, as observed with PPNDS16 and suramin40, which, 
despite inhibiting the RdRp in an isolated enzyme activity assay, demonstrated a lack of antiviral activity in the 
cell-based assay. Compound solubility and its cell-membrane permeability properties could be further improved 
with structure-activity relationship enhancement of the 54 scaffold to facilitate cellular uptake, and therefore to 





IC50 values [µM]A (95% 
confidence interval)
11 506.56 5.0 (2.4–10.6)
13 456.47 15.0 (7.4–27.4)
54 485.52 5.6 (4.1–7.6)
42a 404.45 27.4 (8.3–81.4)
42b 462.48 NDB
Table 2. IC50 values of hit compounds against human norovirus Sydney 2012 RdRp activities. AThe mean values 
of triplicate datasets are shown from at least two independent experiments. BCompound too insoluble to attain 
an accurate IC50 measurement.
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Figure 12. Broad-spectrum activity of hit compounds against calicivirus RdRps and examination of 54 in cell 
culture. (A) Effects of four compounds were evaluated against calicivirus RdRp activities (norovirus, MNV, 
RHDV and sapovirus) using an in vitro fluorescent activity assay at a fixed concentration of 100 µM. The mean 
values of triplicate datasets from at least two independent experiments are shown with standard deviations. (B) 
Dose-response effects of 54 (0.1–100 µM) were examined against MNV RdRp activity in vitro. The IC50 value 
and 95% confidence interval (CI) are shown on the graph. The mean values of triplicate datasets are shown with 
standard deviations. (C) RAW264.7 mouse macrophage cell viability was assessed with 54 (0.5–100 µM). The 
mean values of triplicate datasets from three independent experiments are shown with standard deviations. (D) 
The effects of 54 (0.5–50 µM) were assessed against MNV plaque formation in a plaque reduction assay. The 
mean values of triplicate datasets are shown with standard deviations.
Figure 13. Compound 54 demonstrates competitive binding for the Site-B pocket with PPNDS, but displays 
unique amino acid interactions. (A) Isobologram of 54 (0.1–100 µM) and PPNDS (0.025–10 µM) examined 
in a 4:1 ratio respectively in combination. Together both molecules demonstrate antagonism against human 
norovirus Sydney 2012 RdRp activity with an average combination index of 1.7 over 50%, 75% and 90% 
inhibition. (B) Relative inhibitory effects of 54 on wild-type norovirus Sydney 2012 RdRp activity (red), 
mutants Q414 A (green) and R419A (purple), compared to mock treated samples (vehicle only). The IC50 values 
are shown on the graph. The mean values of triplicate datasets are shown from three independent experiments 
with standard deviations.
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Binding site identification for 54: competitive assay, mutational analyses and molecular dock-
ing studies. Despite the minimal activity in the cell culture system, RdRp inhibition by 54 is an important 
finding in the search of novel norovirus inhibitors. In order to improve the drug-like properties of the molecule 
without negatively influencing the RdRp inhibitory activity, and to design more potent derivatives, knowledge 
of the correct binding site of 54 is fundamental. As mentioned before, the broad-spectrum activity displayed by 
54 could be attributed to a common, highly conserved binding pocket across the RdRps, that could be either 
site-A (suramin) or site-B (PPNDS). 54 and PPNDS were examined in a combinational study to test for antago-
nism (Fig. 13A), which would help demonstrate binding to the same RdRp region. PPNDS (0.025–25 µM) and 
54 (0.1–100 µM) were examined alone and together in a 1:4 ratio respectively (Fig. 13A), and the average of the 
combination indices at 50% (1.6), 75% (1.7) and 90% (1.8) inhibition was 1.7. These results indicate antagonism, 
and therefore likely competitive binding of 54 and PPNDS within RdRp site-B. This is a relevant finding since the 
site-B pocket of the human norovirus RdRp has previously been shown to be an ideal antiviral target due to its 
highly conserved structure16.
Given the evidence of 54 being a site-B binding NNI, residues Q414 and R419 were mutated to alanine. These 
residues were previously shown by our research group and others to be critical for human norovirus RdRp site-B 
binding NNIs, and can create resistance to the drug through their mutagenesis16,17,39. After the mutant RdRps’ 
transcriptional activity was confirmed in a fluorescent RdRp assay (Q414A: 54%, R419A: 34% of wild-type activ-
ity, respectively), dose-response curves for 54 (0.1–100 µM) were produced to compare the IC50 values between 
the wild-type RdRp and the two mutant RdRps, Q414A and R419A (Fig. 13B). The mean IC50 value for the 
wild-type RdRp was 7.4 µM, which was similar to the IC50 values for Q414A RdRp (7.8 µM) and R419A RdRp 
(10.2 µM). The lack of effect of these two mutations on the inhibitory activity of 54, together with the antagonism 
found with PPNDS, suggest that 54 may bind the site-B pocket of the polymerase with no specific interactions 
with Q414 and R419.
Molecular docking evaluations of 54 on the PPNDS binding site of human norovirus RdRp were performed 
using Glide SP. The proposed binding mode is shown in Fig. 14A,B. Compound 54 is predicted to occupy site-B 
in a different orientation compared to PPNDS, spanning an area that includes the central core of site-B and the 
initial part of site-A, where suramin places its sulphate head (Fig. 15). This binding could justify the antagonism 
Figure 14. Proposed binding mode for 54 in the human norovirus RdRp. (A) Compound 54 (carbon atoms in 
lilac) is occupying site-B in a different orientation compared to PPNDS (carbon atoms in pink) with its phenyl-
benzenesulfonamide portion pointing out from the site-B interacting through its sulphonamide group with 
Glu407 and Arg413 and through an arene-cation interaction between Arg392 and the benzene ring. (B) The 
binding site rotated by 180° shows the phenyl-pyrazolidine portion of 54 occupying the area where PPNDS 
places its naphthylazo portion, the core area of site-B, making interactions with the surrounding amino acids 
(Asp507, Glu510). No interactions are present between 54 and the two residues, Glu414 and Arg419. The 
binding site area is represented as molecular surface. Human norovirus RdRp is represented as salmon ribbon.
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results with PPNDS obtained in the combinational study. In fact, the value of 1.7 obtained is an indication of an 
antagonism/moderate-antagonism59, potentially meaning that 54 actually occupies only part of site-B to cause 
the antagonism, but does not occupy the entire site. The phenyl-benzenesulfonamide portion of 54 is pointing 
out from site-B toward the RdRp portion in which site-B and site-A overlap (Arg392 area), interacting through 
its sulphonamide group with Glu407 and Arg413, and through an arene-cation interaction between Arg392 and 
the benzene ring. No interactions are present between the phenyl ring and the protein, therefore its replacement 
by a thiazole, as in the initial hit 11, does not seem to influence binding, in accordance with the similar inhibi-
tory activity found for 54 and 11 in the biological assay. The phenyl-pyrazolidine portion is occupying the area 
where PPNDS places is naphthylazo part (Fig. 14B), within the core area of site-B, making interactions with the 
surrounding amino acids (Asp507, Glu510). The phenyl ring is perfectly fitted for this part of the binding site and 
the presence of substituents in para position could reduce the binding affinity for the site, causing steric clashes 
with the near residues, potentially justifying the minimal RdRp inhibition found for the methyl derivative 55. 
Moreover, even if this portion of 54 is in proximity of Gln414 and Arg419, no interactions are present between 
the molecule and the two residues, in accordance with the lack of effect of the two mutations (Q414A and R419A) 
on the inhibitory activity of 54 (Fig. 13B).
Conclusions and Future Work
A virtual screening evaluation of commercially available, drug-like compounds (~300,000) was performed on the 
suramin and PPNDS binding-sites of the human norovirus RdRp. These two RdRp inhibitors occupy two different 
sites, A and B, situated in the NTP access pathway located between the fingers and thumb domains, and overlap 
each other in the central part of the protein. Selected compounds (n = 62) were examined for inhibition of human 
norovirus RdRp activity using an in vitro transcription assay. Five candidates demonstrated dose-dependent 
RdRp inhibition (>25% inhibition at 10 µM and >50% inhibition at 100 µM), which was confirmed using a 
gel-shift RdRp assay. Among them, two compounds, 11 and 13, were selected for an initial structure-activity rela-
tionship study. Synthetic efforts were made to develop the best synthetic pathway for the preparation of different 
derivatives of both hits. Among the newly prepared compounds, two showed interesting RdRp inhibition profiles. 
The two initial hits 11 and 13, together with the two newly prepared derivatives 42a and 54, displayed IC50 values 
against human norovirus RdRp activity in the micromolar range (5.0–27.4 µM), with the best results obtained for 
11 and its close derivative 54. These four compounds also displayed broad-spectrum inhibitory activity of RdRps 
across three Caliciviridae genera, including Norovirus, Lagovirus and Sapovirus. There is little protein sequence 
identity between the examined calicivirus polymerases (30.2–61.4%), and therefore the broad-spectrum activity 
could be attributed to a common, highly-conserved binding pocket across the RdRps, as has been previously 
reported with broad-spectrum activity of other site-B binding NNIs16. While 54 demonstrated an IC50 of 12.1 µM 
against the MNV RdRp in vitro, it had little effect against MNV in cell culture (EC50 > 50 µM). This could be due 
to poor cell membrane permeability, as previously observed with PPNDS16 and suramin40.
Molecular docking studies revealed that the novel compound 54 is predicted to bind to the central core of 
site-B of the human norovirus RdRp, which has previously been shown to be an ideal antiviral target due to 
its highly conserved structure16. The proposed 54 binding mode was supported by combinational studies with 
PPNDS, the previously reported site-B binding norovirus NNI17. PPNDS and 54 were antagonistic in combina-
tion against norovirus RdRp activity, indicating that both compounds bind in the site-B pocket.
54 may form distinct interactions with other residues within site-B, as mutations of previously reported site-B 
residues (Q414A and R419A) had no appreciable effect on the inhibitory activity of 54 compared to wild-type 
RdRp activity.
Figure 15. Overlap of site-A (suramin) and site-B (PPNDS) on the norovirus RdRp. Superposition of the MNV 
RdRp structure (dark green ribbon) in complex with suramin (carbon atoms in dark purple) and the human 
norovirus RdRp structure (salmon ribbon) in complex with PPNDS (carbon atoms in pink). 54 (carbon atoms 
in lilac) occupies the central core of site-B and extends up to the initial part of site-A (Arg392 area), where 
suramin places its sulphate head.
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The mode of inhibitory action of PPNDS was reported to be through fixation of the C-terminus of the poly-
merase within the active site, blocking incoming NTPs and the RNA template17. It is possible that 54 works in the 
same fashion, and the actual binding site of 54 could be resolved through further crystallography and mutational 
studies.
In conclusion, a novel NNI scaffold, 54, was found to be an effective and specific inhibitor of RdRps across 
three genera of the Caliciviridae, although there was little effect against MNV replication in cell culture, indicat-
ing that cell permeability could be further optimised. In silico and combinational studies suggest that 54 binds 
the highly conserved site-B in the RdRp, and therefore this compound represents a promising starting point for 
further structure-activity relationship enhancement, to improve potency, solubility and specificity profiles in the 
quest for an effective antiviral against human norovirus.
Experimental
Biology. Recombinant RdRp expression, purification and mutagenesis. Recombinant calicivirus RdRps 
(GenBank accession numbers) norovirus GII.Pe/GII.4 Sydney 2012 (KT239579), MNV GV CW1 (DQ285629), 
RHDV Czech V351 (KF594473.1), and SaV GI.1 Mc114 (AY237422) were expressed and purified as described 
previously60,61. RdRp resistance mutants were generated using the QuikChange site-directed mutagenesis kit 
(Agilent Technologies, Santa Clara, CA, USA) and confirmed by Sanger sequencing.
Quantitative RdRp activity and gel-based assays. Fluorescent RdRp activity assays were carried out as previ-
ously described14,62. Briefly, RdRp activity was quantified by monitoring the formation of double-stranded RNA 
(dsRNA) from a single stranded homopolymeric template, poly(C) (Sigma Aldrich, St Louis, MO, USA), using 
the fluorescent dye PicoGreen (Life Technologies, Carlsbad, CA, USA). RdRp assays were performed in 384-well 
plates, and each reaction mixture contained 400 ng enzyme, 45 µM GTP, 10 ng/µL poly(C) RNA, 2.5 mM MnCl2, 
5 mM dithiothreitol, (DTT), 0.01% bovine serum albumin (BSA), and 0.005% Tween 20 in 20 mM Tris-HCl, pH 
7.5, with a final reaction volume of 25 µL. The previous published norovirus NNI NIC02 was used as a positive 
control14. RdRps were incubated for 10 mins at 30 °C in the presence of the test compounds or the compound 
vehicle DMSO (0.5% vol/vol) before addition into the reaction mixture, which was then allowed to run 15 min at 
30 °C then terminated with 10 mM EDTA, followed by PicoGreen staining and dsRNA quantitation. GraphPad 
Prism V6.05 (La Jolla, CA, USA) was used to plot the IC50 values. In cases where fluorescent enhancement was 
recorded for a compound instead of inhibition, a secondary gel-based polymerase activity assay was used as 
a counter-screen as described below, to exclude the possibility of RdRp activity enhancement (Supplementary 
Fig. S1). Primed elongation activity was examined in a gel-based assay as previously described16,63 using the RNA 
template (PE44-NoV, Fig. 4D). Gels were imaged using BioRad (Hercules, CA, U.SA) Geldoc Universal Hood 
II, running BioRad Image Lab software, V4.1, build 16. Antagonism was calculated using Compusyn software 
V1.059. 54 and PPNDS (4:1 ratio) were tested alone and together against norovirus Sydney 2012 RdRp.
The Pseudomonas Φ6 bacteriophage RdRp (NEB) reactions were set up as described above (Fluorescent RdRp 
activity assays), using 400 ng of RdRp per reaction.
Cell culture of MNV and cytotoxicity assays. MNV-1 (CW1) culture assays were performed as previously 
described14. Replication was examined using plaque assays58,64,65. Cytotoxicity was examined using a CellTitre 
Blue (Promega, Madison, WI, USA) viability assay as described previously14.
Inhibition of viral reverse transcriptase. Lead hits were examined for inhibition of Moloney murine leukemia 
virus (MMLV) reverse transcriptase (RT) (kit M02535 (NEB)). MMLV RT activity reactions were carried out 
using 200 U MMLV RT (NEB) per reaction, with 250 ng homopolymeric poly(A) RNA template (average length 
300 nucleotides, Sigma-Aldrich), 50 nM oligo dT15 primer, 1 × MMLV NTP buffer (NEB) and 0.1 mM dTTP in 
a final volume of 25 µL. The RT was incubated with the compound or the compound vehicle (0.5% DMSO) for 
10 min, and then reactions were initiated by the addition of the RNA and primer mix. The reaction was incubated 
for 1 h at 42 °C then the RT was deactivated by incubation at 65° for 20 min. Picogreen stain was added and the 
relative fluorescence was measured as described above in the ‘Quantitative RdRp activity and gel-based assays’ 
section.
Molecular Modelling. All molecular modelling studies were performed on a Viglen Genie Intel®CoreTM 
i7-3770 vPro CPU@ 3.40 GHz × 8 running Ubuntu 14.04. Molecular Operating Environment (MOE) 2015.1066, 
Maestro (Schrödinger Release 2017–1), LeadIT (version 2.1.8), OpenEye Scientific Software and PLANTS were 
used as molecular modelling software. Pharmacophoric filters were created within MOE choosing the PCH 
(polar-charged-hydrophobic) scheme. Shape-comparison screening was performed with ROCS version 3.2.1.4. 
Both shape and color screen criteria were applied to the query. Output conformations were ranked according to 
the Tanimoto combo score and the shape Tanimoto score. A library of commercially available compounds was 
downloaded from SPECS website (www.specs.net) in sdf format and prepared using the Conformational Search 
tool in MOE for the pharmacophore studies and the Omega version 2.5.1.4 for the shape-based screening.
RdRp crystal structures were downloaded from Protein Data Bank (PDB) (http://www.rcsb.org/); PDB code 
3UR0 (suramin), 4LQ3 (PPNDS) and prepared with the MOE Protein Preparation tools for the pharmacophore 
studies and PLANTS docking. Docking PLANTS simulations for the virtual screening were performed using 
the following parameters: search algorithm: aco_ants 20, aco_evap 0.15, aco_sigma 2.0; binding site: binding-
site_center [−2.665 5.272 33.756] for suramine crystal [−19.229 −25.402 −4.634] for PPNDS crystal, binding-
site_radius 10; cluster algorithm: cluster_rmsd 2.0, cluster_strucures 5; scoring function: chemplp. The docking 
results obtained were then rescored using Glide XP and FlexX scoring functions.
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Docking of 54 in the PPNDS binding site was performed using Glide docking program. The RdRp structure 
co-crystallised with PPNDS (PDB code: 4LQ3) was prepared using the Schrödinger Protein Preparation Wizard 
by assigning bond orders, adding hydrogens and performing a restrained energy minimization of the added 
hydrogens using the OPLS_2005 force field. An 11 Å docking grid (inner-box 11 Å and outer-box 220 Å) was 
prepared using as centroid the co-crystallised structure of PPNDS. Molecular docking of 54 was performed using 
Glide SP precision keeping the default parameters and setting 10 as number of output poses to include in the 
solution. The docking output database was saved as mol2 file and the docking poses visually inspected for their 
binding mode in MOE.
The visual inspection process, conducted as last step of the structure-based and the ligand-based virtual 
screening, was performed using MOE 2015.10. The docking poses of the compounds obtained from the consensus 
score procedure were evaluated considering the following criteria:
•	 ability of a compound to overall occupy the binding site (suramine or PPNDS binding site);
•	 number of interactions formed between the compound and the target protein (H-bonds, pie-pie interactions, etc.);
•	 coverage of different chemical scaffolds, discarding similar chemical entities;
•	 potential chemical instability;
•	 presence of potential toxic groups (multiple halogen atoms, aldehyde, etc.).
Chemistry. All solvents and reagents were used as obtained from commercial sources unless otherwise indi-
cated. All solvents used for chromatography were HPLC grade from Fisher Scientific (UK). All reactions were 
performed under a nitrogen atmosphere. 1H and 13C NMR spectra were recorded with a Bruker Avance DPX500 
spectrometer operating at 500 MHz for 1H and 125 MHz for 13C, with Me4Si as internal standard. Deuterated 
chloroform was used as the solvent for NMR experiments, unless otherwise stated. 1H chemical shifts values (δ) 
are referenced to the residual non-deuterated components of the NMR solvents (δ = 7.26 ppm for CHCl3, etc.). 
The 13C chemical shifts (δ) are referenced to CDCl3 (central peak, δ = 77.0 ppm). Mass spectra were determined 
with a Bruker microTOF spectrometer using electrospray ionization (ESI source). For mass spectra, solutions 
were made in HPLC grade methanol. TLC was performed on silica gel 60 F254 plastic sheets. Flash column 
chromatography was performed using silica an Isolera Biotage system. UPLC-MS analysis was used for purity/
mass determination of the tested compounds using a Waters UPLC system with both Diode Array detection 
and Electrospray (+’ve and –‘ve ion) MS detection. The stationary phase was a Waters Acquity UPLC BEH C18 
1.7 um 2.1 × 50 mm column. The mobile phase was H2O containing 0.1% Formic acid (A) and MeCN containing 
0.1% Formic acid (B). Column temperature: 40 °C. Sample diluent: acetonitrile. Sample concentration 1 µg/mL. 
Injection volume 2 µL. A linear gradient standard method (A) was used: 90% A (0.1 min), 90–0% A (2.6 min), 0% 
A (0.3 min), 90% A (0.1 min); flow rate 0.5 mL/min. All compounds tested in biological assays were >95% pure. 
Purity of intermediates was >90%, unless otherwise stated.
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